{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"Engraftment is the process of transplanted stem cells reproducing new cells.","groups":[{"description":"Participants received thalidomide every night (at bedtime) without food on Days 1 to 28 and dosing was gradually increased during Cycle 1 starting at 50 mg on Days 1 to 7, 100 mg on Days 8 to 14, 150 mg on 15 to 21, and 200 mg on Days 22 to 28. Thalidomide 200 mg per day was administered for subsequent cycles. Dexamethasone 40 mg was administered by mouth on Days 1 to 4, 9 to 12 and 17 to 20.","id":"OG000","title":"Thalidomide + Dexamethasone"},{"description":"DOXIL 40 mg/m2 was administered intravenously on Day 1 and thalidomide every night (at bedtime) without food on Days 1-28 and dosing was gradually increased during Cycle 1 starting at 50 mg on Days 1 to 7, 100 mg on Days 8 to 14, 150 mg on 15 to 21, and 200 mg on Days 22 to 28. Thalidomide 200 mg per day was administered for subsequent cycles. Dexamethasone 40 mg was administered by mouth on Days 1 to 4, 9 to 12 and 17 to 20.","id":"OG001","title":"DOXIL + Thalidomide + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat: Participants who were randomized to receive the treatment and who underwent transplantation.","reportingStatus":"POSTED","timeFrame":"From randomization until death or as assessed up to 2 years post last participant last treatment visit","title":"Engraftment: Number of Participants Who Underwent Engraftment","type":"SECONDARY","unitOfMeasure":"Participants"}